Page last updated: 2024-11-03

primaquine and Aging

primaquine has been researched along with Aging in 4 studies

Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
" There was no evidence of symptomatic hemolysis, and adverse events considered related to study drug (n = 4) were mild."1.48Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial. ( Bousema, T; Brown, J; Chen, I; Diarra, K; Diawara, H; Dicko, A; Djimde, M; Gosling, R; Greenhouse, B; Hwang, J; Keita, M; Keita, S; Kone, D; Mahamar, A; Murphy, M; Niemi, M; Pett, H; Roh, ME; Sanogo, K, 2018)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19902 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, I1
Diawara, H1
Mahamar, A1
Sanogo, K1
Keita, S1
Kone, D1
Diarra, K1
Djimde, M1
Keita, M1
Brown, J1
Roh, ME1
Hwang, J1
Pett, H1
Murphy, M1
Niemi, M1
Greenhouse, B1
Bousema, T1
Gosling, R1
Dicko, A1
Betuela, I1
Bassat, Q1
Kiniboro, B1
Robinson, LJ1
Rosanas-Urgell, A1
Stanisic, D1
Siba, PM1
Alonso, PL1
Mueller, I1
BREWER, GJ1
POWELL, RD1
SWANSON, SH1
ALVING, AS1
Goldschmidt, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali[NCT02535767]Phase 1/Phase 228 participants (Actual)Interventional2015-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

4 other studies available for primaquine and Aging

ArticleYear
Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial.
    The Journal of infectious diseases, 2018, 03-28, Volume: 217, Issue:8

    Topics: Adolescent; Adult; Aging; Antimalarials; Child; Child, Preschool; Dose-Response Relationship, Drug;

2018
Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:4

    Topics: Aging; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Cohort Studies

2012
HEMOLYTIC EFFECT OF PRIMAQUINE. XVII. HEXOKINASE ACTIVITY OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT AND NORMAL ERYTHROCYTES.
    The Journal of laboratory and clinical medicine, 1964, Volume: 64

    Topics: Aging; Anemia, Hemolytic; Biomedical Research; Black People; Bloodletting; Erythrocyte Aging; Erythr

1964
Variations in red cell glutathione with aging in male and female primaquine-sensitive Negroes.
    Clinical biochemistry, 1971, Volume: 4, Issue:1

    Topics: Adult; Aged; Aging; Black People; Computers; Erythrocytes; Female; Glucosephosphate Dehydrogenase De

1971